Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 73 | ECE2021 | Next issue

European Congress of Endocrinology 2021

Online
22 May 2021 - 26 May 2021

Card image cap
The European Congress of Endocrinology provides a global platform for the international endocrine community to discuss the latest advances in the field.

Presented Eposters

Presented ePosters 8: Pituitary and Neuroendocrinology

ea0073pep8.1 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Oral octreotide capsules lowered incidence and improved severity of acromegaly symptoms compared to injectable somatostatin receptor ligands—results from the MPOWERED trial

Biermasz Nienke , Fleseriu Maria , Dreval Alexander V , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E , Macut Djuro P , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H , Patou Gary , Haviv Asi , Gordon Murray B , Urbanavicius Vaidotas , Knispelis Robertas , Melmed Shlomo K , Strasburger Christian J

BackgroundPatients with acromegaly may have high symptom burden. The phase 3 MPOWERED trial assessed control of acromegaly by oral octreotide capsules (OOC; MYCAPSSA®) in comparison to injectable somatostatin receptor ligands (iSRLs) in patients responding to both OOC and iSRLs. iSRLs have been first-line medical treatment for patients with acromegaly for decades. OOC are newly approved in the US for patients previously controlled on iSRL...

ea0073pep8.2 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Antioxidant response to DNA oxidative damage in adult growth hormone deficiency: a pilot study

Vergani Edoardo , Bruno Carmine , Guidi Francesco , Angelini Flavia , Lanza Paola , Aversa Luigi , Gavotti Cesare , Silvestrini Andrea , Mancini Antonio

Adult growth hormone deficiency (GHD), a condition characterized by increased oxidative stress (OS), is related to augmented cardiovascular, metabolic and oncological risk. Thymidine-glycol (ThyG) (5, 6-dihydro-5, 6-dihydroxy-2’-deoxythymidine) is a marker of DNA oxidation produced when thymidine is damaged by hydroxyl radicals. It is considered a specific marker since it is not incorporated in RNA; while 8-OH-deoxyguanosine, a well-known marker of oxidative damage, is ra...

ea0073pep8.3 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy

Fleseriu Maria , Dreval Alexander V. , Pokramovich Yulia , Bondar Irina , Isaeva Elena , Molitch Mark E. , Macut Djuro P. , Leonova Nina , Raverot Gerald , Yossi Gilgun-Sherki , Ludlam William H. , Patou Gary , Haviv Asi , Gordon Murray B. , Verbovoy Andrey , Dogadin Sergey A. , Biermasz Nienke , Strasburger Christian J. , Melmed Shlomo K.

BackgroundOral octreotide capsules (OOC; MYCAPSSA®) are approved in the US for individuals with acromegaly who responded to and tolerated treatment with injectable somatostatin receptor ligands (iSRLs). Add-on cabergoline therapy has shown effectiveness in patients previously inadequately controlled with iSRLS.1 The phase 3 MPOWERED trial assessed maintenance of response with OOC compared to iSRLs. Patients receiving OOC and in...

ea0073pep8.4 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Whole exome sequencing (WES) reveals oligogenic aetiology in a case of combined pituitary hormone deficiency (CPHD)

Sertedaki Amalia , Tatsi Elizabeth , Vassilakis Ioannis Anargyros , Nikaina Eirini , Fylaktou Eirini , Iacovidou Nikoletta , Siahanidou Soultana , Kanaka-Gantenbein Christina

Background CPHD is characterized by GH and at least one other pituitary hormone deficiency. Mutations in genes expressed in the developing head, hypothalamus, and/or pituitary cause CPHD. To date around 30 genes have been identified to be related to CPHD, however 85% of the cases remain with unknown molecular aetiology.Patient and methodsA newborn boy (46, XY) delivered by CS due to IUGR with a birthweight of...

ea0073pep8.5 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Osilodrostat provides sustained control of urinary free cortisol in patients with Cushing’s disease: final results from a prospective, open-label study (LINC 2)

Fleseriu Maria , Biller Beverly , Bertherat Jerome , Young Jacques , Arnaldi Giorgio , O’Connell Paul , Izquierdo Miguel , Pedroncelli Alberto , Pivonello Rosario

IntroductionThe oral 11β-hydroxylase inhibitor, osilodrostat, normalized mean urinary free cortisol (mUFC) in 79% (15/19) of patients with Cushing’s disease at the end of the 22-week core LINC 2 study. Long-term efficacy and safety data following an optional extension phase are reported here.MethodsPatients with clinical benefit at week 22 could continue receiving osilodrostat during the extension; ...

ea0073pep8.6 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Can the follow-up imaging interval for non-functioning pituitary microadenomas be extended?

Han Ashley , Varlamov Elena , Fleseriu Maria

BackgroundData on clinical characteristics and natural history of patients with non-functioning pituitary microadenomas (NFPmA) is limited to small-scale studies.MethodsA retrospective evaluation of initial clinical presentation and natural history of patients with NFPmA (conservatively managed, years; 2004–2020) was undertaken. Initial symptoms, tumor size, and pituitary function were assessed. Exclusio...

ea0073pep8.7 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Russian hypothalamic and pituitary tumor registry (OGGO): current results

Lutsenko Alexander , Przhiyalkovskaya Elena , Belaya Zhanna , Vikulova Olga , Pigarova Ekaterina , Zenkova Tatiana , Mamedova Elizaveta , Grebennikova Tatiana , Dzeranova Larisa , Rozhinskaya Liudmila , Marova Evgenia

BackgroundPituitary disease registries are major instruments of epidemiological and clinical data collection used worldwide.ObjectiveTo assess the data of pituitary tumor registry in Russia.Material and methodsPatient records, retrieved from online platform of the Registry.ResultsCurrently there are 9858 patients regis...

ea0073pep8.8 | Presented ePosters 8: Pituitary and Neuroendocrinology | ECE2021

Diagnosis and treatment of patients with neuroendocrine tumours: evidence from specialist Polish centres

Bartmanska Marta , Bednarczuk Tomasz , Daria Handkiewicz-Junak , Alicja Hubalewska-Dydejczyk , Kaminski Grzegorz , Kolasinska-Ćwikla Agnieszka , Kudla Beata Kos , Kowalska Aldona , Ruchala Marek , Syrenicz Anhelli

BackgroundOptimal management of patients with neuroendocrine tumours (NETs) is essential to ensure the best treatment results. This survey aimed to obtain a comprehensive picture of NET management in Poland by examining the pathway of patients with NETs throughout their diagnosis and treatment.MethodsPhysicians treating patients with NET in 17 Polish clinical centres/hospital wards, covering approximately 80%...